Search This Blog

Wednesday, January 31, 2024

Ensysce: Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

 ~ PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 ~

https://www.accesswire.com/viewarticle.aspx?id=829496

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)